HEALTH CARE:
PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS
Acquires, develops and commercializes novel pharmaceutical products for the treatment of life-threatening diseases. As of Dec. 31, 2005, the company's lead product candidates were Sulonex for the treatment of diabetic nephropathy and KRX-0401 for the treatment of multiple forms of cancer.
| Market Cap | 478.072 Million | Shares Outstanding | 119.22 Million | Avg Volume | 2.345 Million |
| 1-Yr BETA vs S&P TR | 0.954 | Current Ratio | 3.12 | Quick Ratio | 2.49 |
| Q2 2018 | All Institutions | Hedge Funds 1 |
|---|---|---|
| To trade KERX now: | |
|
| Filers who had this stock in their top 10: | 0 | 0 (0.0%) |
| 13F Filers holding this stock: | 126 | 21 (2.01%) |
| Aggregate 13F shares on 06/30/2018: | 71.697 Million | 38.517 Million |
| Aggregate 13F shares on 03/31/2018: | 74.37 Million | 37.931 Million |
| Percent change: | -3.59% | 1.54% |
| Funds creating new positions: | 22 | 6 |
| Funds Adding to an existing position: | 39 | 7 |
| Funds closing out their position: | 15 | 4 |
| Funds reducing their position: | 32 | 3 |
| 1 hedge funds as identified by whalewisdom.com through public filings. | ||
View recent insider trading info
Keryx Biopharmaceuticals Inc Chart by YCharts
Please sign in first
none
none
none
| Reporting Owners | Transaction Date | Transaction Code | Shares | Acquired or Disposed | Shares Owned Following Transaction | Direct/Indirect Ownership |
|---|---|---|---|---|---|---|
| No current insider transactions | ||||||
